Patents by Inventor William J. McClellan

William J. McClellan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BROMODOMAIN INHIBITORS
    Publication number: 20230158039
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: June 30, 2022
    Publication date: May 25, 2023
    Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
  • BROMODOMAIN INHIBITORS
    Publication number: 20210236508
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: August 18, 2020
    Publication date: August 5, 2021
    Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
  • BROMODOMAIN INHIBITORS
    Publication number: 20180296566
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: June 19, 2018
    Publication date: October 18, 2018
    Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20180251426
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: October 13, 2017
    Publication date: September 6, 2018
    Inventors: Milan Bruncko, Yujia Dai, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron R. Kunzer, Robert A. Mantei, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, William J. McClellan
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20180193315
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1-Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 12, 2018
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • Bromodomain inhibitors
    Patent number: 9994581
    Abstract: The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: June 12, 2018
    Assignee: AbbVie Inc.
    Inventors: Le Wang, Robin R. Frey, Todd M. Hansen, Dachun Liu, William J. McClellan, Keith F. McDaniel, John K. Pratt, Carol K. Wada
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20180071262
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: October 6, 2017
    Publication date: March 15, 2018
    Applicant: AbbVie Inc.
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • BROMODOMAIN INHIBITORS
    Publication number: 20170015673
    Abstract: The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: December 10, 2014
    Publication date: January 19, 2017
    Inventors: Le Wang, Robin R. Frey, Todd M. Hansen, Dachun Liu, William J. McClellan, Keith F. McDaniel, John K. Pratt, Carol K. Wada
  • DIHYDRO-PYRROLOPYRIDINONE INHIBITORS
    Publication number: 20160237084
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: April 25, 2016
    Publication date: August 18, 2016
    Inventors: Le Wang, John Pratt, Lisa A. Hasvold, Dachun Liu, Yujia Dai, Steven D. Fidanze, James H. Holms, Robert A. Mantei, Keith F. McDaniel, George S. Sheppard, William J. McClellan
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20160235716
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1- - - -Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: September 17, 2015
    Publication date: August 18, 2016
    Applicant: ABBVIE INC.
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • BROMODOMAIN INHIBITORS
    Publication number: 20160143916
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: January 28, 2016
    Publication date: May 26, 2016
    Inventors: Le Wang, John K. Pratt, Keith F. McDaniel, Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James H. Holms, Warren M. Kati, Dachun Liu, Robert A. Mantei, William J. McClellan, George S. Sheppard, Carol K. Wada
  • Dihydro-pyrrolopyridinone inhibitors
    Patent number: 9321764
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 26, 2016
    Assignee: AbbVie Inc.
    Inventors: Le Wang, John Pratt, Lisa A. Hasvold, Dachun Liu, Yujia Dai, Steven D. Fidanze, James H. Holms, Robert A. Mantei, Keith F. McDaniel, George S. Sheppard, William J. McClellan
  • Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
    Patent number: 9315488
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 19, 2016
    Assignee: ABBVIE INC.
    Inventors: Hong Ding, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, William J. McClellan, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Michael D. Wendt
  • Bromodomain inhibitors
    Patent number: 9296741
    Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 29, 2016
    Assignee: AbbVie Inc.
    Inventors: Le Wang, John K Pratt, Keith F McDaniel, Yujia Dai, Steven D Fidanze, Lisa Hasvold, James H Holms, Warren M Kati, Dachun Liu, Robert A Mantei, William J McClellan, George S Sheppard, Carol K Wada
  • BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
    Publication number: 20160009687
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: May 29, 2015
    Publication date: January 14, 2016
    Inventors: Hong Ding, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, William J. McClellan, Gerard M. Sullivan, Andrew J. Souers, Zhi-Fu Tao, Michael D. Wendt
  • Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
    Patent number: 9125913
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 8, 2015
    Assignee: AbbVie Inc.
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, Robert A. Mantei, William J. McClellan, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt
  • BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
    Patent number: 9072748
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: July 7, 2015
    Assignee: AbbVie Inc.
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, Robert A. Mantei, William J. McClellan, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20150183775
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: December 23, 2014
    Publication date: July 2, 2015
    Inventors: Milan BRUNCKO, Yujia DAI, Hong DING, George A. DOHERTY, Steven W. ELMORE, Lisa HASVOLD, Laura HEXAMER, Aaron R. KUNZER, Robert A. MANTEI, Chang H. PARK, Cheol-Min PARK, Andrew M. PETROS, Xiaohong SONG, Andrew J. SOUERS, Gerard M. SULLIVAN, Zhi-Fu TAO, Gary T. WANG, Le WANG, Xilu WANG, Michael D. WENDT, William J. MCCLELLAN
  • DIHYDRO-PYRROLOPYRIDINONE INHIBITORS
    Publication number: 20140275026
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Le Wang, John Pratt, Lisa A. Hasvold, Dachun Liu, Yujia Dai, Steven D. Fidanze, James H. Holms, Robert A. Mantei, Keith F. McDaniel, George S. Sheppard, William J. McClellan
  • APOPTOSIS PROMOTERS
    Publication number: 20140187531
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.
    Type: Application
    Filed: March 3, 2014
    Publication date: July 3, 2014
    Applicant: AbbVie Inc.
    Inventors: Milan Bruncko, Hong Ding, Steven W. Elmore, Aaron R. Kunzer, Christopher L. Lynch, William J. McClellan, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Xilu Wang, Noah P. Tu, Michael D. Wendt, Alexander R. Shoemaker, Michael J. Mitten